Compare Estee Lauder Companies Inc (EL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Estee Lauder Companies Inc trades at $97.63 (market cap $34.17B), while State Street SPDR S&P Biotech ETF trades at $153.13 (market cap $10.11B). The key difference: Estee Lauder Companies Inc is far larger — about 3.4× State Street SPDR S&P Biotech ETF's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| EL | XBI | |
|---|---|---|
Market Cap | $34.17B | $10.11B |
Volume | 3,921,497 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $119.61 | $169.55 |
52-Week Low | $67.23 | $104.99 |
Typical Hold Time | 122 Days | 37 Days |
Enterprise Value | $39.92B | — |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though 2025 results showed a net loss of $1.13B on $14.33B revenue. Analyst consensus is mixed with 48% buy ratings and a $103 price target, while recent news highlights AI partnerships and leadership changes driving strategic repositioning.
The stock presents a turnaround opportunity with strong brand positioning and digital initiatives, but faces execution risks from recent profitability challenges and high debt levels. Near-term catalysts include Q3 earnings and continued margin recovery, though competitive pressures and macroeconomic sensitivity remain headwinds for the luxury beauty sector.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
